Lubris生物制药

2021年4月9日

图片来源:盖蒂图片社的普遍的生物传感器,Inc . (ASX:无论何时)股价飙升的今天,上涨了36%。积极的价格波动在两公司公告:癌症检测技术协议,独家供应协议。在撰写本文时,股价在医疗诊断公司65美分,射击后的52周高点85美分附近的开放。让我们仔细看看今天的公告以及它们如何可能会影响股价普遍的生物传感器。癌症检测技术在澳交所首次声明,该公司宣布,“已经进入与Lubris生物制药有限责任公司独家许可证和供应协议…”商业化生物传感器测试能够检测和监控的癌症。通用表示,Tn生物传感器由迪肯大学联合开发,斯文本科技大学和卧龙岗大学的使用技术由Lubris提供。通用生物传感器和Lubris之间的协议将是全球性的,排他的,永久的,涵盖所有知识产权,商业化,开发和制造的权利。普遍的生物传感器将拥有所有新知识产权。生物传感器已经临床1000例病人身上进行试验。在这宣布,通用生物传感器的首席执行官约翰·沙曼说:能够识别和测量,然后监控的一个健康的人体细胞变成癌细胞从手持医疗点生物传感器装置是一个令人兴奋的前景无论在哪里。 …the blood testing market for the monitoring of cancer remission patients annually is estimated at $17 billion. It would be wonderful if this initiative could improve the lives of many of the 131 million cancer remission patients around the world. He added: The next step to develop a commercial product is to ensure the Tn biosensor can be reproduced on our manufacturing line and measured reliably using patients’ whole blood. Based on our initial feasibility we estimate this could take 3 years and cost between $5 – $7 million. UBI has $25 million of cash reserves and no debt. Exclusive supply agreement In its second statement that is shooting up the Universal Biosensors share price today, the company updated an exclusive, global supply agreement with Lubris. Lubris will supply Universal Biosensors with an antifouling coating called Lubricin that, when applied to an electrochemical biosensor, can improve its detection power by 1 million times more. It can be used in many applications, including human health, veterinary science, wine testing, and environmental research. According to Universal Biosensors, the supply agreement does not contain any specific minimum purchase requirements. However, if Universal Biosensors is unsuccessful in commercialising its product, the agreement will become non-exclusive. Speaking on the supply agreement, Mr Sharman said: The agreement for the supply of Lubricin for use on UBI’s electrochemical biosensor platform is a generational advancement for UBI’s technology. Our strategy is to partner with companies that have developed biosensors in large markets which can be used on our hand-held platform technology. Our ambition is to develop a stable of revenue generating biosensor products capable of detecting analytes of interest in key industries, Universal Biosensors share price snapshot Including today massive increase, the Universal Biosensors share price has gained 261% over the past 12 months and is up 37% year-to-date. Universal Biosensors has a market capitalisation of $122.9 million. Where to invest $1,000 right now When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more. * Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now. These stocks could rocket in a Post-COVID world In this FREE STOCK REPORT, Scott Phillips just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. By clicking this button, you agree to our Terms of Service and Privacy Policy . We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe at anytime. Please refer to our Financial Services Guide (FSG) for more information. Browse Articles by Category